CAS: 1614262-83-7

NITD-916: oral Mycobacterium InhA inhibitor (IC50: 570 nM), lipophilic 4-hydroxy-2-pyridone with antituberculosis action.

NITD-916 is an antiviral compound, which is a synthetic molecule designed for therapeutic purposes. Its source lies in medicinal chemistry, where it was developed through a detailed process of molecular optimization and testing to enhance its efficacy and pharmacokinetic properties. The mode of action of NITD-916 involves inhibiting viral replication by targeting specific non-structural proteins essential for the replication process of certain RNA viruses. NITD-916 has been primarily investigated for its potential applications against flaviviruses, which include significant pathogens such as dengue and Zika viruses. By impeding the replication of these viruses, NITD-916 renders them incapable of progressing within the host, thereby reducing the viral load and mitigating the severity of the infection. This compound has been studied in vitro and in vivo, demonstrating significant promise in preclinical trials, paving the way for further development and clinical evaluation. Its role in antiviral research highlights the critical need for novel therapeutics in combating emerging viral threats.

NITD-916